このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

IRLAB Therapeutics マネジメント

マネジメント基準チェック /24

IRLAB Therapeutics'の CEO はGunnar Olssonで、 Feb2023年に任命され、の在任期間は 1.33年です。の年間総報酬はSEK 3.10Mで、 96.6%給与と3.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.012%を直接所有しており、その価値はSEK 81.02K 。経営陣と取締役会の平均在任期間はそれぞれ11.4年と2.1年です。

主要情報

Gunnar Olsson

最高経営責任者

SEK 3.1m

報酬総額

CEO給与比率	96.6%
CEO在任期間	1.4yrs
CEOの所有権	0.01%
経営陣の平均在職期間	11.5yrs
取締役会の平均在任期間	2.2yrs

経営陣の近況

Recent updates

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25

CEO報酬分析

IRLAB Therapeutics の収益と比較して、Gunnar Olsson の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-SEK 119m
Mar 31 2024	n/a	n/a	-SEK 157m
Dec 31 2023	SEK 3m	SEK 3m	-SEK 178m
Sep 30 2023	n/a	n/a	-SEK 176m
Jun 30 2023	n/a	n/a	-SEK 162m
Mar 31 2023	n/a	n/a	-SEK 144m
Dec 31 2022	SEK 517k	n/a	-SEK 113m
Sep 30 2022	n/a	n/a	-SEK 103m
Jun 30 2022	n/a	n/a	SEK 42m
Mar 31 2022	n/a	n/a	SEK 43m
Dec 31 2021	SEK 450k	n/a	SEK 52m
Sep 30 2021	n/a	n/a	SEK 55m
Jun 30 2021	n/a	n/a	-SEK 93m
Mar 31 2021	n/a	n/a	-SEK 93m
Dec 31 2020	SEK 450k	n/a	-SEK 92m
Sep 30 2020	n/a	n/a	-SEK 99m
Jun 30 2020	n/a	n/a	-SEK 93m
Mar 31 2020	n/a	n/a	-SEK 98m
Dec 31 2019	SEK 205k	n/a	-SEK 96m
Sep 30 2019	n/a	n/a	-SEK 88m
Jun 30 2019	n/a	n/a	-SEK 83m
Mar 31 2019	n/a	n/a	-SEK 76m
Dec 31 2018	SEK 205k	n/a	-SEK 74m
Sep 30 2018	n/a	n/a	-SEK 68m
Jun 30 2018	n/a	n/a	-SEK 73m
Mar 31 2018	n/a	n/a	-SEK 60m
Dec 31 2017	SEK 80k	n/a	-SEK 56m

報酬と市場: Gunnarの総報酬 ($USD 296.82K ) は、 Swedish市場 ($USD 257.78K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Gunnarの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Gunnar Olsson (71 yo)

1.4yrs

在職期間

SEK 3,097,380

報酬

Mr. Gunnar Olsson has been a Director at IRLAB Therapeutics AB (publ) since 2017 and served as its Chairman since May 7, 2020 until February 2023 and is its Interim Chief Executive Officer since February 2...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Gunnar Olsson	Interim CEO & Director	1.4yrs	SEK 3.10m	0.012% SEK 93.9k
Viktor Siewertz	Chief Financial Officer	7.5yrs	データなし	0.46% SEK 3.7m
Clas Sonesson	Chief Scientific Officer	11.5yrs	データなし	1.46% SEK 11.9m
Peder Svensson	Chief Information Officer and Director of Computational Chemistry & Biology	11.5yrs	データなし	0.50% SEK 4.1m
Tove Bergenholt	Global IR & Communications	no data	データなし	データなし
Cecilia Stenberg	Head of Finance & Human Resource and Director of Accounting & Human Resources	11.5yrs	データなし	0.70% SEK 5.7m
Nicholas Waters	Executive VP and Head of R&D	no data	SEK 1.70m	1.44% SEK 11.7m
Joakim Tedroff	Chief Medical Officer	11.5yrs	SEK 5.00k	1.22% SEK 9.9m

11.5yrs

平均在職期間

62.5yo

平均年齢

経験豊富な経営陣: IRLAB Aの経営陣は経験豊富で経験豊富です（平均在職期間は11.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Gunnar Olsson	Interim CEO & Director	7.5yrs	SEK 3.10m	0.012% SEK 93.9k
Rein Piir	Independent Director	8.5yrs	SEK 256.25k	0.081% SEK 655.7k
Carola Lemne	Independent Chairman of the Board	6.5yrs	SEK 400.00k	0.027% SEK 219.1k
Christer Nordstedt	Director	1.1yrs	SEK 147.50k	データなし
Veronica Wallin	Independent Director	1.1yrs	SEK 160.00k	データなし
Catharina Wallich	Independent Director	2.2yrs	SEK 264.17k	0.015% SEK 125.2k
Daniel Johnsson	Director	1.1yrs	SEK 175.00k	8.71% SEK 70.7m

2.2yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: IRLAB Aの取締役会は経験豊富ではない ( 2.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

IRLAB Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

Director recently bought kr260k worth of stock

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

Recent updates

IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee

Price target decreased by 7.1% to kr56.63

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

IRLAB Therapeutics AB (publ) Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Director recently bought kr260k worth of stock

IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

New major risk - Financial position

IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

Consensus revenue estimates increase by 88%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I

IRLAB Therapeutics AB (publ) Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection

New minor risk - Profitability

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Price target increased by 83% to kr59.05

Second quarter 2023 earnings released

IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat (IRL752) Are Activated and Recruiting Patients

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics Updates on Portfolio Development Milestones

IRLAB Therapeutics Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson’s Disease

IRLAB Therapeutics AB Nominates IRL1117 as Drug Candidate from the P003 Project to Develop a Novel Treatment for Parkinson's Disease

IRLAB Therapeutics AB Reports Last Patient Last Visit (“Lplv”) Achieved in Phase Iib Clinical Study of Mesdopetam in Pd-Lids with Top-Line Results Anticipated Mid-January 2023

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

IRLAB Therapeutics AB (publ) to Report Q1, 2023 Results on May 10, 2023

IRLAB Therapeutics AB Announces New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Consensus forecasts updated

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

Consensus forecasts updated

Irlab Therapeutics AB (Publ) Expands Phase IIb/III Pd-Lids Study with Mesdopetam to Support Phase Iii Program and Expects Completion of Enrollment During the Summer

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

IRLAB Therapeutics AB (publ) Approves Board Appointments

Price target increased to kr69.50

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Independent Vice Chairman of the Board recently bought kr330k worth of stock

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2021 Results on Apr 08, 2022

Independent Chairman recently bought kr74k worth of stock

Irlab Obtains Regulatory Approval to Conduct Phase IIb Study with Pirepemat

Independent Director recently bought kr112k worth of stock

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Chief Medical Officer recently sold kr1.8m worth of stock

Independent Director has left the company

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

IRLAB Announces First Patients in Europe Dosed in the clinical Phase IIb/III Study with Mesdopetam

New 90-day low: kr36.50

New 90-day low: kr38.55

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

マネジメント基準チェック /24